AIM: Although agents that target FRA have advanced through clinical trials, comprehensive analyses of FRA expression in epithelial cancers compared with clinical variables and prognosis are limited. MATERIALS & METHODS: FRA expression was examined in non-small-cell lung cancer (NSCLC), ovarian cancer and endometrial cancer cohorts using AQUA(®) technology. RESULTS: For the NSCLC cohort, FRA expression was significantly higher in adenocarcinoma samples (p < 0.001) than other histologies, and in females (p = 0.003) versus males. High FRA expression was significantly associated with better survival in NSCLC cases (p = 0.01) while significantly and independently associated with worse prognosis in endometrial (p < 0.001) and ovarian cancers (p < 0.001). CONCLUSION: These studies confirm the prognostic value of FRA in multiple indications. The opposing prognostic effects observed may suggest differential biology.
AIM: Although agents that target FRA have advanced through clinical trials, comprehensive analyses of FRA expression in epithelial cancers compared with clinical variables and prognosis are limited. MATERIALS & METHODS:FRA expression was examined in non-small-cell lung cancer (NSCLC), ovarian cancer and endometrial cancer cohorts using AQUA(®) technology. RESULTS: For the NSCLC cohort, FRA expression was significantly higher in adenocarcinoma samples (p < 0.001) than other histologies, and in females (p = 0.003) versus males. High FRA expression was significantly associated with better survival in NSCLC cases (p = 0.01) while significantly and independently associated with worse prognosis in endometrial (p < 0.001) and ovarian cancers (p < 0.001). CONCLUSION: These studies confirm the prognostic value of FRA in multiple indications. The opposing prognostic effects observed may suggest differential biology.
Authors: Daniel J O'Shannessy; Elizabeth B Somers; Lakshmi K Chandrasekaran; Nicholas C Nicolaides; Jennifer Bordeaux; Mark D Gustavson Journal: Oncotarget Date: 2014-06-30